Drug wins ASCO standing ovation

Posted 5 June 2024 AM

AstraZeneca received a standing ovation at the American Society of Clinical Oncology (ASCO) 2024 annual meeting after presenting astonishing trial results for its EGFR inhibitor Tagrisso.

There is a reduction of 84 per cent in the risk of disease progression or death when using Tagrisso to treat patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) whose tumours have exon 19 deletions or exon 21 (L858R) mutations, after chemoradiotherapy (CRT) compared to a placebo, according to results from the LAURA Phase 3 trial.

To see the whole article, please login